Affiliations 

  • 1 Department of Medicine, Faculty of Medicine and Health Sciences (FMHS), Universiti Malaysia Sarawak (UNIMAS), Jalan Datuk Mohammad Musa, 94300, Kota Samarahan, Sarawak, Malaysia. kuanjewwin@gmail.com
  • 2 Department of Community Medicine and Public Health, FMHS, UNIMAS, Kota Samarahan, Sarawak, Malaysia
  • 3 Department of Pathology, FMHS, UNIMAS, Kota Samarahan, Sarawak, Malaysia
  • 4 Department of Para-Clinical Sciences, FMHS, UNIMAS, Kota Samarahan, Sarawak, Malaysia
  • 5 Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan
  • 6 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
  • 7 Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan. sashidag@kumamoto-u.ac.jp
Int J Hematol, 2020 Feb;111(2):217-224.
PMID: 31707540 DOI: 10.1007/s12185-019-02768-x

Abstract

The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the International Scale (qPCRIS). BCR-ABL1 has also been found in asymptomatic normal individuals using a non-qPCRIS method. In the present study, we examined the prevalence of BCR-ABL1 in a normal population in southern Sarawak by performing qPCRIS for BCR-ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. While 146 of 190 (76.8%) or 102 of 190 (53.7%) samples showed sufficient amplification of the ABL1 gene at > 20,000 or > 100,000 copy numbers, respectively, in qPCRIS, one of the 190 samples showed amplification of BCR-ABL1 with positive qPCRIS of 0.0023% and 0.0032% in two independent experiments, the sequence of which was the BCR-ABL1 e13a2 transcript. Thus, we herein demonstrated that the BCR-ABL1 fusion gene is expected to be present in approximately 0.5-1% of normal individuals in southern Sarawak.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.